Lipid pharmacotherapy for treatment of atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Atherosclerosis Research

Background:

• Low-density lipoprotein cholesterol reduction has been central to managing atherosclerotic cardiovascular disease for over 20 years.
• Despite statin therapy, a significant residual risk of clinical events persists, necessitating improved cardiovascular risk reduction strategies.

Purpose of the Study:

• To discuss current and future therapeutic approaches for dyslipidemia and inflammation in atherosclerosis.
• To evaluate the potential of novel strategies in managing atherosclerotic cardiovascular disease.

Main Methods:

• Review of current and emerging therapeutic targets for dyslipidemia.
• Discussion of strategies targeting inflammatory factors in atherosclerosis.
• Analysis of the role of lipoproteins and inflammatory mediators.

Main Results:

• Further reductions in atherogenic lipoproteins offer additional avenues for cardiovascular risk reduction.
• The clinical benefit of targeting protective lipid factors remains uncertain.
• The efficacy of targeting inflammatory mediators in atherosclerosis requires further investigation.

Conclusions:

• Continued efforts to lower atherogenic lipoproteins are valuable for reducing cardiovascular risk.
• The clinical utility of targeting protective lipids or inflammatory pathways in atherosclerosis needs further validation.
• Optimizing lipid management and exploring novel anti-inflammatory approaches are crucial for comprehensive cardiovascular disease prevention.